GGiantBullStocks

Tango Therapeutics, Inc. (TNGX)

NASDAQ · Healthcare

$27.54-3.57%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$3.81B
P/E ratio
EPS
Volume
1,231,121
52-week high
52-week low
Open
$28.50
Day high
$29.34
Day low
$27.51

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$62.38M-$101.59M-$0.87
2024$42.07M-$130.3M-$1.19
2023$36.53M-$101.74M-$1.08
2022$24.86M-$108.18M-$1.23
2021$37.04M-$58.24M-$0.94

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

CEO
Malte Peters
Employees
155
Country
US
IPO date
Sep 3, 2020

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Tango Therapeutics, Inc.'s stock price today?
TNGX is trading at $27.54 as of Jul 20, 2026.
What is Tango Therapeutics, Inc.'s market cap?
Tango Therapeutics, Inc. (TNGX) has a market capitalization of $3.81B.
Does Tango Therapeutics, Inc. pay a dividend?
Tango Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is Tango Therapeutics, Inc. in?
Tango Therapeutics, Inc. operates in the Healthcare sector.